MedTrace Logo

Identification of Biomarkers and Molecular Targets Involved on Intervertebral Disc Degeneration and Discogenic Pain

NCT06349226 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 160

Last updated 2024-04-05

No results posted yet for this study

Summary

Low back pain, associated with intrinsic disorders of the spine, is a very frequent clinical condition that is accompanied by high morbidity with effects both on psychosocial aspects, and health care system. It occurs in approximately 80% of the population throughout their lives. Most low back pain is associated with intervertebral disc degeneration (IDD) associated with neuroinflammation and pain. In this context, the study of sphingolipid metabolism can play an important role in the identification of new molecules responsible for the degenerative process. Sphingolipids, in fact, are a class of molecules that are implicated in multiple signal pathways, such as proliferation, degradation of the extracellular matrix, inflammatory state, apoptosis and migration. In particular, sphingosine-1-phosphate (S1P), an intermediate of sphingolipid metabolism, acts as a pro-inflammatory mediator, predominantly in the extracellular environment, regulating important cellular properties related to inflammatory potential and pain. The objective of this study is to characterize the degenerative process in cells isolated from degenerated human intervertebral discs from both at cellular and molecular levels in order to identify new targets implicated in degenerative processes, including sphingolipid signaling pathway.

Conditions

  • Intervertebral Disc Degeneration
  • Discogenic Pain
  • Discogenic Disease

Interventions

OTHER

cell isolation from intervertebral disc tissue and biomarker investigation

metabolomic, cellular and molecular analysis on intervertebral disc derived cells and investigation of tissue neuroinflammatory and pain-related biomarkers

Sponsors & Collaborators

  • Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

    lead OTHER

Principal Investigators

  • Marco Locatelli, MD, PhD · Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Neurosurgery Unit

  • Mauro Pluderi, MD · Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Neurosurgery Unit

  • Giovanni Marfia, MD, PhD · Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Neurosurgery Unit, Istituto di Medicina Aerospaziale di Milano, CeMATA - Aeronautica Militare

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-22
Primary Completion
2025-05-21
Completion
2025-05-21

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06349226 on ClinicalTrials.gov